Skip to main content

NovaBridge Biosciences

corporate_fare Company Profile

NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed NBP - Latest Insights

NBP
Apr 28, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
8
NBP
Apr 22, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
NBP
Apr 07, 2026, 4:50 PM EDT
Source: GlobeNewswire
Importance Score:
7
NBP
Apr 07, 2026, 4:48 PM EDT
Filing Type: 20-F
Importance Score:
9
NBP
Mar 16, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
NBP
Mar 09, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
9
NBP
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
NBP
Mar 03, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
NBP
Feb 25, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
9
NBP
Feb 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
NBP
Feb 17, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
NBP
Feb 06, 2026, 8:30 AM EST
Filing Type: 6-K
Importance Score:
9
NBP
Feb 03, 2026, 4:13 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
NBP
Jan 16, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
NBP
Jan 06, 2026, 7:02 AM EST
Filing Type: 6-K
Importance Score:
9